Naloxegol for the Treatment of Opioid-Induced Constipation in Patients with Cancer Pain: A Pooled Analysis of Real-World Data
Authors:
- Jean-Marc SabatéJean-Marc Sabaté
- Carmen Beato-ZambranoCBCarmen Beato-Zambrano
- Manuel CoboMCManuel Cobo
- Antoine LemaireAntoine Lemaire
- Vincenzo MontesarchioVMVincenzo Montesarchio
- Judith Serna-MontrosJSJudith Serna-Montros
- Rafik NamaneRNRafik Namane
- Santiago Martín BaccarelliSBSantiago Martín Baccarelli
- Fernando Rico-VillademorosFRFernando Rico-Villademoros
Open Access
Abstract
Objective: The aim of the NALOPOOL project was to assess the efficacy and safety of naloxegol in patients with cancer pain who exhibited opioid-induced constipation (OIC) and were treated under real-world conditions. Methods: We pooled individual patient data from three multicenter observational studies conducted with naloxegol in patients with cancer who exhibited OIC and were prescribed naloxegol under real-world conditions. Efficacy outcomes were evaluated after 4 weeks of treatment. All analyses were performed via a visit-wise approach. Heterogeneity was assessed via Cochran’s Q-test or Levene’s test. Results: Spontaneous bowel movements (SBM) response (≥3 SBM per week and an increase of ≥1 from baseline; three studies) was reported in 223 of 314 evaluable patients (71%, 95% CI 66–76); clinically relevant improvement in the Patient Assessment of Constipation Quality-of-Life Questionnaire (>0.5 points; three studies) occurred in 179 of 299 evaluable patients (60%, 95% CI 56–74) and in the Patient Assessment of Constipation Symptoms (>0.5 points; two studies) was reported in 131 of 190 evaluable patients (69%, 95% CI 62–76); and clinically relevant improvement in the Bowel Function Index (score ≥ 12 points at the endpoint; two studies;) was reported in 133 of 195 evaluable patients (68%, 95% CI 62–75). No significant heterogeneity was found for any efficacy outcome. The pooled proportion of patients who discontinued the drug owing to adverse reactions was 6.1% (95% CI 3.8% to 8.4%). Conclusions: Our results support the use of naloxegol for the management of OIC in patients with cancer pain who do not respond to laxative treatment.Keywords
Funding Information
- Kyowa Kirin International
This publication has 37 references indexed in Scilit:
- Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipationSupportive Care in Cancer, 2021
- What to Do and What Not to Do in the Management of Opioid-Induced Constipation: A Choosing Wisely ReportPain and Therapy, 2020
- 1871P Overcoming barriers in opioid-induced constipation managementAnnals of Oncology, 2020
- Opioid-Induced Constipation in Oncological Patients: New Strategies of ManagementCurrent Treatment Options in Oncology, 2019
- Challenges in Recruiting Patients to a Controlled Feasibility Study of a Drug for Opioid-Induced Constipation: Lessons From the Population With Advanced CancerJournal of Pain and Symptom Management, 2019
- Rome IV—Functional GI Disorders: Disorders of Gut-Brain InteractionGastroenterology, 2016
- Bowel DisordersGastroenterology, 2016
- Opioid-induced constipation, use of laxatives, and health-related quality of lifeScandinavian Journal of Pain, 2016
- Randomised controlled trials and population-based observational research: partners in the evolution of medical evidenceBritish Journal of Cancer, 2014
- Validation of the PAC‐SYM questionnaire for opioid‐induced constipation in patients with chronic low back painEuropean journal of pain, 2006